Atlantic Equities analyst Hamilton Faber upgrades Spotify Technology (NYSE:SPOT) from Neutral to Overweight and announces $160 price target.
Why Is Arthritis-Focused Aclaris Therapeutics Stock Nosediving Today?
Aclaris Therapeutics Inc (NASDAQ: ACRS) shares plunged after the company released topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to